<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172586</url>
  </required_header>
  <id_info>
    <org_study_id>502.316</org_study_id>
    <nct_id>NCT02172586</nct_id>
  </id_info>
  <brief_title>Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients</brief_title>
  <official_title>A PROBE (Prospective, Randomised, Open-label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80 mg Once Daily Compared With Losartan 50-100 mg Once Daily Over a Period of 12 Weeks, and of Telmisartan 80 mg + HCTZ 12.5 mg Once Daily Compared With Losartan 100 mg Once Daily + HCTZ 12.5 mg Once Daily Over a Period of Further 12 Weeks in Mild to Moderate Hypertensive Patients (Grade 1 and Grade 2 WHO-ISH Guidelines 1999)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the efficacy of telmisartan 40-80 mg once daily compared with losartan 50-100&#xD;
      mg once daily in hypertensive patients evaluated by change from baseline in diastolic blood&#xD;
      pressure (DBP) during the last 6 hours of the 24-hour dosing interval, at the end of the 12&#xD;
      weeks period of monotherapy treatment (ABPM - ambulatory blood pressure measurement).&#xD;
&#xD;
      Secondary objectives: Changes from baseline in BP at the end of the monotherapy period of&#xD;
      treatment and at the end of the study, evaluated by sphygmomanometric blood pressure&#xD;
      measurement and ABPM&#xD;
&#xD;
      Safety:&#xD;
&#xD;
      Incidence of adverse events (AE's); withdrawal due to adverse events; laboratory parameters&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in diastolic blood pressure (DBP) during the last 6 hours (ABPM - ambulatory blood pressure measurement) of the 24-hour dosing interval at the end of the monotherapy period of treatment</measure>
    <time_frame>Baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DBP during the last 6 hours (ABPM) of the 24-hour dosing interval at the end of the study</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure (SBP) during the last 6 hours (ABPM) of the 24-hour dosing interval</measure>
    <time_frame>Baseline, week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DBP/SBP during the last 2 hours (ABPM) of the 24-hour dosing interval (trough BP)</measure>
    <time_frame>Baseline, week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in trough cuff (sphygmomanometer) SBP/DBP</measure>
    <time_frame>Baseline, week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in SBP/DBP of 24 hours mean ABPM</measure>
    <time_frame>Baseline, week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of SBP/DBP ABPM tracing profile</measure>
    <time_frame>Week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoothness index in comparison with baseline</measure>
    <time_frame>Baseline, week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders</measure>
    <time_frame>Week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of controlled responders</measure>
    <time_frame>Week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who withdraw due to lack of efficacy</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who withdraw due to adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan + Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan + Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_label>Telmisartan + Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_label>Losartan + Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <arm_group_label>Losartan + Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Telmisartan + Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Mild-to-moderate essential hypertension defined as a mean diastolic blood pressure&#xD;
             (DBP) ≥ 95 mmHg and &lt; 110 mmHg and systolic blood pressure (SBP) &lt; 180 mmHg measured&#xD;
             by manual cuff sphygmomanometer at the end of the wash-out period&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nursing, pregnancy or childbearing potential women, post-menopausal women will be&#xD;
             enrolled with last menstruation &gt; 1 year prior to start wash-out phase or surgically&#xD;
             sterile&#xD;
&#xD;
          -  Secondary hypertension&#xD;
&#xD;
          -  Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)&#xD;
&#xD;
          -  Clinically significant sodium depletion as defined by serum sodium level &lt; 130 mEq/L&#xD;
             and/or clinically significant hyperkaliemia as defined by serum potassium level &gt; 5.5&#xD;
             mEq/L or clinically significant hypokaliemia as defined by serum potassium level &lt; 3.0&#xD;
             mEq/L&#xD;
&#xD;
          -  Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which,&#xD;
             in the investigator opinion could compromise patient's participation to the trial&#xD;
&#xD;
          -  Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF&#xD;
             III-IV)&#xD;
&#xD;
          -  Angina pectoris or myocardial infarction&#xD;
&#xD;
          -  Cardiac surgery within the past 3 months prior to start the wash-out period&#xD;
&#xD;
          -  Stroke within the past 6 months prior to start the wash-out period&#xD;
&#xD;
          -  Renal insufficiency defined as creatininaemia &gt; 2mg/dl&#xD;
&#xD;
          -  Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post&#xD;
             renal transplant, presence of only one functioning kidney&#xD;
&#xD;
          -  Liver insufficiency, defined as bilirubinaemia &gt; 2mg/dl and AST (aspartate&#xD;
             aminotransferase) or ALT (alanine-aminotransferase) &gt; twice the upper normal range&#xD;
&#xD;
          -  Clinically significant metabolic and endocrine disease&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Previous history of angioedema&#xD;
&#xD;
          -  Body mass index &gt; 30kg/m2&#xD;
&#xD;
          -  Arm circumference &gt; 32 cm&#xD;
&#xD;
          -  Any condition that may be likely to compromise patients participation to the trial&#xD;
             (alcohol or drug abuse, disability illness, etc.)&#xD;
&#xD;
          -  Concomitant therapy with antihypertensive drugs non permitted by protocol,&#xD;
             corticosteroids or drugs known to affect blood pressure&#xD;
&#xD;
          -  Concomitant use of lithium or cholestyramine or colestipol resins (potential drug&#xD;
             interactions with HCTZ)&#xD;
&#xD;
          -  Investigational drug treatment within the past 30 days before the enrolment or&#xD;
             concurrent participation to any other trial&#xD;
&#xD;
          -  Sensitivity, significant adverse reaction or contraindications to the study drugs&#xD;
             (telmisartan, losartan, HCTZ)&#xD;
&#xD;
          -  Predictable lack of patient co-operation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.316.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

